NCT07316296

Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Radboud University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if the medication atomoxetine can reduce freezing of gait in people with Parkinson's disease. The main questions it aims to answer is: Does atomoxetine reduce the frequency or severity of freezing of gait? What role does noradrenaline play in freezing of gait? Researchers will compare atomoxetine to a placebo to see if atomoxetine can improve freezing of gait in people with Parkinson's disease. Participants will: Visit the study site for measurements Take atomoxetine or placebo Perform walking assessments and undergo MRI Complete questionnaires about anxiety, stress, and quality of life

Conditions

• Parkinson's Disease (PD)
• Freezing of Gait
• Freezing of Gait Symptoms in Parkinson Disease

Interventions

Type	Name	Description
DRUG	Atomoxetine	Single dose, 40mg atomoxetine, capsule
DRUG	Placebo	Single dose, placebo (microcrystalline cellulose), capsule

Timeline

• Start date: 2026-01-01
• Primary completion: 2027-07-01
• Completion: 2027-12-31
• First posted: 2026-01-05
• Last updated: 2026-02-27

Locations

1 site across 1 country: Netherlands